Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014

  • Share on Google+

Global Markets Direct

2014 Jun 30

202 Pages (PDF)




Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014

Summary

Global Markets Directs, Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014, provides an overview of the Wet (Neovascular / Exudative) Macular Degenerations therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Wet (Neovascular / Exudative) Macular Degeneration Overview 8
Therapeutics Development 9
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 9
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis 10
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 11
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 19
Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 22
Alcon Nordic A/S 22
Genzyme Corporation 23
Boehringer Ingelheim GmbH 24
F. Hoffmann-La Roche Ltd. 25
Allergan, Inc. 26
pSivida Corp. 27
Quark Pharmaceuticals, Inc. 28
Santen Pharmaceutical Co., Ltd. 29
Oxford BioMedica plc 30
EyeGate Pharmaceuticals, Inc. 31
Novartis AG 32
Pfizer Inc. 33
Tacere Therapeutics, Inc. 34
iCo Therapeutics Inc. 35
Lpath, Inc. 36
Mesoblast Limited 37
Circadian Technologies Limited 38
Ophthotech Corp. 39
Sanwa Kagaku Kenkyusho Co., Ltd. 40
Regeneron Pharmaceuticals, Inc. 41
ThromboGenics NV 42
Intas Pharmaceuticals Ltd. 43
Senju Pharmaceutical Co., Ltd. 44
Neurotech Pharmaceuticals, Inc. 45
Iconic Therapeutics, Inc. 46
Omeros Corporation 47
Charlesson LLC. 48
TRACON Pharmaceuticals, Inc. 49
EyeCyte, Inc. 50
PanOptica, Inc. 51
Ohr Pharmaceutical Inc. 52
Pfenex Inc. 53
Kala Pharmaceuticals, Inc. 54
Icon Bioscience, Inc. 55
Amakem NV 56
BIOCAD 57
AlphaMab Co., Ltd 58
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Target 60
Assessment by Mechanism of Action 63
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 71
aflibercept - Drug Profile 71
E-10030 - Drug Profile 74
bevacizumab biosimilar - Drug Profile 76
ranibizumab biosimilar - Drug Profile 77
LT-1009 - Drug Profile 78
ocriplasmin - Drug Profile 82
NT-503 - Drug Profile 85
PF-655 - Drug Profile 86
fluocinolone acetonide - Drug Profile 88
AGN-150998 - Drug Profile 90
squalamine lactate - Drug Profile 92
KH-902 - Drug Profile 94
LFG-316 - Drug Profile 96
RTH-258 - Drug Profile 98
Allogeneic Mesenchymal Precursor Cells For Macular Degeneration - Drug Profile 100
BI-144807 - Drug Profile 101
ALG-1001 - Drug Profile 102
AVA-101 - Drug Profile 104
SK-1011 - Drug Profile 106
ARC-1905 - Drug Profile 107
triamcinolone acetonide - Drug Profile 108
hI-con1 - Drug Profile 109
X-82 - Drug Profile 110
ranibizumab biosimilar - Drug Profile 111
DE-120 - Drug Profile 112
bertilimumab - Drug Profile 113
RetinoStat - Drug Profile 115
GZ-402663 - Drug Profile 116
PAN-90806 - Drug Profile 117
PF-05206388 - Drug Profile 119
REGN-2176-3 - Drug Profile 120
RG-7716 - Drug Profile 121
Lpathomab - Drug Profile 122
OMS-721 - Drug Profile 123
CLT-005 - Drug Profile 125
TRC-105 - Drug Profile 126
OPT-302 - Drug Profile 128
XV-615 - Drug Profile 129
AGN-151200 - Drug Profile 130
NT-506 - Drug Profile 131
SNJ-1945 - Drug Profile 132
Drug for Wet Age-Related Macular Degeneration - Drug Profile 133
EC-400 - Drug Profile 134
Monoclonal Antibody for Age Related Macular Degeneration - Drug Profile 135
TT-231 - Drug Profile 136
AMA-0428 - Drug Profile 137
Drug For Wet Age Related Macular Degeneration - Drug Profile 138
Antibody for Wet AMD - Drug Profile 139
ranibizumab biosimilar - Drug Profile 140
EC-200 - Drug Profile 141
TT-211 - Drug Profile 142
Drugs For Retinal Eye Diseases - Drug Profile 143
ENV-705 - Drug Profile 144
Small Molecules for Age Related Macular Degeneration - Drug Profile 145
Wet (Neovascular / Exudative) Macular Degeneration - Recent Pipeline Updates 146
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 187
Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 188
Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 189
Featured News & Press Releases 189
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 198
Disclaimer 198
Alcon Nordic A/S 
Genzyme Corporation 
Boehringer Ingelheim GmbH 
F. Hoffmann-La Roche Ltd. 
Allergan, Inc. 
pSivida Corp. 
Quark Pharmaceuticals, Inc. 
Santen Pharmaceutical Co., Ltd. 
Oxford BioMedica plc 
EyeGate Pharmaceuticals, Inc. 
Novartis AG 
Pfizer Inc. 
Tacere Therapeutics, Inc. 
iCo Therapeutics Inc. 
Lpath, Inc. 
Mesoblast Limited 
Circadian Technologies Limited 
Ophthotech Corp. 
Sanwa Kagaku Kenkyusho Co., Ltd. 
Regeneron Pharmaceuticals, Inc. 
ThromboGenics NV 
Intas Pharmaceuticals Ltd. 
Senju Pharmaceutical Co., Ltd. 
Neurotech Pharmaceuticals, Inc. 
Iconic Therapeutics, Inc. 
Omeros Corporation 
Charlesson LLC. 
TRACON Pharmaceuticals, Inc. 
EyeCyte, Inc. 
PanOptica, Inc. 
Ohr Pharmaceutical Inc. 
Pfenex Inc. 
Kala Pharmaceuticals, Inc. 
Icon Bioscience, Inc. 
Amakem NV 
BIOCAD 
AlphaMab Co., Ltd				
Full Name
Email
Job Title
Mobile
Your Requirement
Full Name
Email
Job Title
Mobile
Your Requirement